Fedir Hladkykh

Dr. Fedir Hladkykh

National Academy of Sciences of Ukraine, Kyiv, Kyyiv, Misto, Ukraine
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Journal of Pain Research
Verified
Journal Article
Open access
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
TLTetiana Liadova
Tetiana Liadova
MMMariia Matvieienko
Mariia Matvieienko
RKRoman Komorovsky
Roman Komorovsky
SSSvitlana Smiyan
Svitlana Smiyan
VSVolodymyr Student
Volodymyr Student
Central sensitization explains the mismatch between structural damage or inflammation and pain intensity in chronic musculoskeletal diseases. It defines the phenotype of fibromyalgia and contributes to persistent pain in osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. To characterize the role of central sensitization in nociplastic pain in fibromyalgia, osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. A structured search of PubMed, Scopus, Web of Science, and Google Scholar (1990–2025) identified open-access, evidence-based publications addressing pain pathophysiology, diagnosis, and treatment in these conditions. Central sensitization manifests as hyperalgesia, allodynia, expanded receptive fields, and impaired endogenous pain inhibition. It predominates in fibromyalgia and contributes to persistent pain in osteoarthritis and rheumatoid arthritis that may not correlate with inflammation or structural damage. Screening tools such as the Widespread Pain Index and Symptom Severity Scale, together with quantitative sensory testing and algometry, help identify nociplastic pain features. Neuroimmune mechanisms, including microglial activation and imbalance between excitatory and inhibitory neurotransmission, may contribute to the mismatch between pain intensity and clinical findings. Chronic pain reflects inflammatory, mechanical, and nociplastic mechanisms in rheumatoid arthritis, osteoarthritis, and fibromyalgia, respectively. Recognition of central sensitization improves assessment and supports mechanism-based management.

1 August 2025 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
OGOlena Garmish
Olena Garmish
SSSvitlana Smiyan
Svitlana Smiyan
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
BKBohdan Koshak
Bohdan Koshak
RKRoman Komorovsky
Roman Komorovsky
Patients with inflammatory joint diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, have an elevated risk of cardiovascular complications due to systemic inflammation, immune-mediated endothelial dysfunction, and associated metabolic changes. Disease-modifying antirheumatic drugs (DMARDs) influence cardiovascular risk through their effects on inflammation, lipid metabolism, and endothelial function. Methotrexate has demonstrated cardioprotective properties, likely mediated through anti-inflammatory mechanisms rather than direct metabolic effects. However, other conventional DMARDs, such as sulfasalazine and hydroxychloroquine, also continue to play a role in routine practice; their cardiovascular effects appear more heterogeneous and less well established. Biologic DMARDs, particularly tumor necrosis factor (TNF) inhibitors, are associated with a reduction in major cardiovascular events despite inducing lipid profile alterations. However, data on newer biologic agents, such as interleukin (IL)-17 and IL-23 inhibitors, remain limited. Janus kinase (JAK) inhibitors present concerns regarding dyslipidemia and thrombotic risk, necessitating individualized cardiovascular risk assessment. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain controversial due to their potential to exacerbate cardiovascular risk, particularly with long-term use. Given the variability in drug effects, treatment strategies must balance effective disease control with cardiovascular safety. This narrative review summarizes current evidence on the impact of both conventional and biologic DMARDs on cardiovascular risk, drawing from randomized clinical trials and real-world observational data. The review also compares available data across different inflammatory joint diseases and highlights areas of uncertainty that remain in clinical decision-making. A multidisciplinary and individualized approach remains essential for optimizing long-term cardiovascular outcomes in these patients.

5 September 2022 in Innovative Biosystems and Bioengineering
Verified
Journal Article
Open access
PDF file
Koshurba IlliaKoshurba Illia
Koshurba Illia
MCMykola Chyzh
Mykola Chyzh
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
IBIryna Belochkina
Iryna Belochkina
Background. Viral hepatitis is one of the most common and dangerous diseases in the world and is the third most common infectious disease. The development of new, more effective and safer hepatoprotective drugs is an urgent task of biomedicine. A wide range of proven biological properties in cryoextract of human placenta, in particular the presence of antioxidant, immunomodulating and anti-inflammatory effects, suggests that it has a hepatoprotective effect. A model of D-galactosamine toxic hepatitis, which is similar to human viral hepatitis in terms of morphological and biochemical changes in the liver, was chosen for the study. Objective. We are aimed to study the effect of the therapeutic and preventive administration of cryopreserved placenta extract on the metabolic and functional state of the liver in the model of D-galactosamine hepatitis in rats. Methods. The study was conducted on 28 male rats weighing 200–220 g. Hepatitis was simulated by a single intraperitoneal injection of a 20% aqueous solution of D-galactosamine at a dose of 400 mg/kg. The cryoextract was administered in the treatment-prophylactic mode – 1 time per day for 3 days before the administration of D-galactosamine and another 2 days after the administration of the aminosugar (5 administrations in total). Results. The development of experimental D-galactosamine hepatitis in rats leads to the formation of functional and metabolic disorders in the form of the activation of lipid peroxidation processes, a violation of pigment metabolism, a decrease in the protein-synthesizing function and the development of cytolytic syndrome, which were indicated by an increase (p < 0.001) in the level of reactants with thiobarbituric acid in liver homogenates by 2.2 times, an increase (p < 0.001) in the level of total bilirubin by 2.5 times, a decrease (p < 0.001) in the albumin-globulin ratio by 46.8% and an increase (p < 0.001) in the level of alanine-aminotransferases by 2.2 times and the level of aspartate-aminotransferases by 70.3% compared to the values ​​of intact animals. Against the background of the administration of placenta cryoextract in experimental hepatitis, the level of reactants with thiobarbituric acid decreased (p < 0.001) by 43.8%, the level of alanine-aminotransferases decreased (p < 0.001) by 2.4 times, and the level of aspartate-aminotransferases decreased (p < 0.001) by 45.3%; the level of total protein increased (p < 0.01) by 17.4%, and the level of total bilirubin decreased (p < 0.001) by 53.5% compared to the indicators of untreated animals. Conclusions. Administration of cryopreserved placenta extract normalized metabolic processes in the liver and restored its functional state due to antioxidant and membrane-stabilizing effects, which weakened the cytolytic syndrome caused by the administration of D-galactosamine and restored the protein-synthesizing function of the liver. In addition, administration of the specified cryoextract neutralized D-galactosamine-induced hyperbilirubinemia.

1 December 2021 in AFMN Biomedicine
Verified
Journal Article
Open access
PDF file
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
Non-steroidal anti-inflammatory drugs (NSAIDs) are ranked first among the world's effective anti-inflammatory and analgesic drugs with anticipated side effects. That is why the prevention of development of adverse reactions associated with NSAIDs, in particular, of those related to their ulcerogenicity, remains a serious global problem. Aims. To characterize the mechanisms of gastrocytoprotective activity of cryopreserved placenta in combined action of low temperatures and diclofenac sodium. The study was performed on 42 male rats weighing 200-220 g. Acute diclofenac sodium-induced gastropathy was reproduced by a single injection of the latter in rats at the dose of 50 mg/kg. The content of malonic dialdehyde, catalase activity, prostaglandin synthase activity and the content of nitrogen monoxide metabolites in homogenates of gastric mucosa were determined by spectrophotometric method. The study showed that prophylactic administration of placental cryoextract in rats with diclofenac sodium-induced gastropathy is associated with increased activity of antioxidant system in gastric mucosa as demonstrated by an elevated catalase activity by 40.0% as compared with control rats. Modulation of antioxidant-prooxidant homeostasis is believed to be one of the principal mechanisms of gastrocytoprotective action in combined action of low temperatures and cryoextract of the placenta. This is shown by a statistically significant (p < 0.05) 2.2-fold increase of antioxidant-prooxidant index in the study group as compared with rats with diclofenac sodium-induced gastropathy. Administration of placental cryoextract was found to increase prostaglandin synthase activity in rats with diclofenac sodium-induced gastropathy by two times as compared with control rats, which would reduce iatrogenic prostaglandin deficiency in gastric mucosa. Also, the combined action of low temperatures and of placenta cryoextract was associated with a statistically significant (p < 0.05) increase in the level of metabolites of nitrogen monoxide (by 70.1%) as compared with rats with diclofenac sodium-induced gastropathy. Modulation of prooxidant-antioxidant homeostasis in gastric mucosa and increase in contents of nitrogen monoxide metabolites and prostaglandin synthase activity are the leading mechanisms of gastroprotective activity of cryopreserved placental extract in diclofenac sodium-induced gastropathy.


1 January 2022
Verified
Book
Closed access
Fedir HladkykhFedir Hladkykh
Fedir Hladkykh
The monograph is focused on the accumulated experimental data regarding the innovative approach to optimization the pharmacological effects of nonsteroidal anti-inflammatory drugs by means of their combined use with drugs that have multifunctional properties. The results of our own research on the effectiveness of the use of cryopreserved placenta extract and vinboron to reduce the ulcerogenic effect of nonsteroidal anti-inflammatory drugs are summarized. New data on enhancement of therapeutic efficacy via the combined use of nonsteroidal anti-inflammatory drugs and drugs with pleiotropic pharmacological properties are presented. The monograph will be useful for a wide range of clinicians, pharmacologists, biochemists, pathophysiologists, as well as for medical, pharmacy and biology students. Tables – 43, figures – 55, bibliography – 268 references. Монографію присвячено експериментальному обґрунтуванню інноваційного підходу до вирішення актуальної проблеми сучасної медицини – оптимізації фармакологічних ефектів нестероїдних протизапальних засобів шляхом їх комбінованого застосування з препаратами, яким притаманні поліфункціональні властивості. Наведено узагальнення результатів власних досліджень ефективності використання кріоконсервованого екстракту плаценти та вінборону з метою послаблення ульцерогенної дії нестероїдних протизапальних засобів. Представлено нові дані щодо посилення терапевтичної ефективності на тлі комбінованого застосування нестероїдних протизапальних засобів та препаратів з політропними фармакологічними властивостями. Монографія буде корисною для широкого кола лікарів-клініцистів, фармакологів, біохіміків, патофізіологів, а також здобувачів закладів вищої освіти медичного, фармацевтичного та біологічного профілів. Таблиць – 43, рисунків – 55, бібліографія – 268 посилань.